XML 62 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of net revenue from collaboration arrangement

Net revenue recognized under our GSK Agreements was as follows:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2024

 

 

2023

 

 

2022

 

Royalties – RELVAR/BREO

 

$

207,925

 

 

$

208,042

 

 

$

215,034

 

Royalties – ANORO

 

 

47,631

 

 

 

44,627

 

 

 

38,405

 

Royalties – TRELEGY(1)

 

 

 

 

 

 

 

 

72,029

 

Total royalties

 

 

255,556

 

 

 

252,669

 

 

 

325,468

 

Less: amortization of capitalized
   fees paid

 

 

(13,823

)

 

 

(13,823

)

 

 

(13,823

)

Total royalty revenue

 

$

241,733

 

 

$

238,846

 

 

$

311,645

 

 

(1) The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.

Schedule of net product sales

Total net product sales was as follows:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2024

 

 

2023

 

 

2022

 

GIAPREZA®

 

$

55,037

 

 

$

41,294

 

 

$

14,214

 

XERAVA®

 

 

21,385

 

 

 

17,320

 

 

 

5,480

 

XACDURO®

 

 

21,070

 

 

 

2,003

 

 

 

 

    Total net product sales

 

$

97,492

 

 

$

60,617

 

 

$

19,694